Human placental transfer of atazanavir: A case report [5]

AIDS

Volumn 20, Issue 2, 2006, Pages 307-

  Lechelt, Martin ^a   Lyons, Fiona ^a   Clarke, Amanda ^a   Magaya, Veronica ^a   Issa, Rosanna ^a   De Ruiter, Annemiek ^a  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIRETROVIRUS AGENT; ATAZANAVIR; LAMIVUDINE; NEVIRAPINE; PROTEINASE INHIBITOR; TENOFOVIR;

ADULT; CASE REPORT; DRUG BLOOD LEVEL; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; PLACENTAL TRANSFER; PREGNANCY; PRIORITY JOURNAL; TREATMENT OUTCOME; VIRUS LOAD;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MATERNAL-FETAL EXCHANGE; OLIGOPEPTIDES; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PYRIDINES;

EID: 33646060425     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000202653.49020.dd     Document Type: Letter

References (3)

1. Marzolini C, Rudin C, Decosterd LA, Telenti A, Schreyer A, Biollaz J, and the Swiss Mother + Child HIV Cohort Study. Transplacental passage of protease inhibitors at delivery. AIDS 2002; 16:889-893.
2. Busti AJ, Hall RG, Margolis DM. Atazanavir in the treatment of human immunodeficiency virus infection. Pharmacotherapy 2004; 24:1732-1747.
3. Gonzalez de Requena D, Bonora S, Cantra F, Marrone R, D'Avolio A, Sciandra M, et al. Atazanavir Ctrough is associated with efficacy and safety: definition of therapeutic range. In: 12th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA, 22-25 February 2005 [Abstract 645].